BRCA1 and BRCA2 genes mutations among women with clinical signs of hereditary breast cancer in western Belarus
Abstract
Background: Breast cancer is the most common malignancy in women. In the countries of Central and Eastern Europe founder mutations in the BRCA1 and BRCA2 genes are responsible for a significant proportion of breast cancer cases; however, regional differences in the frequencies of various mutations may occur. The spectrum and frequency of BRCA1 and BRCA2 mutations among breast cancer patients have not yet been fully explored in Belarus. Aim: In this study, we aimed to estimate the incidence of BRCA1 and BRCA2 causative founder variants in breast cancer female patients with clinical signs of hereditary disease in western Belarus. Materials and Methods: Blood samples from 71 breast cancer female patients with clinical signs of hereditary disease from the western region of Belarus were examined. We studied 13 causative founder variants in BRCA1 (c.5266dupC, c.4035delA, c.5251C>T, c.181T>G, c.676delT, c.68_69delAG, c.3770_3771delAG, c.1687C>T, c.3756_3759delGTCT) and BRCA2 (c.658_659delGT, c.7910_7914delCCTTT, c.3847_3848delGT, c.5946delT) genes characteristic for the population of Central Europe. The study included 22 female patients with early-onset form, 8 individuals with bilateral and 41 women with multiple primary breast cancer. Results: 32 out of 71 patients (45 %) had one of the causative founder variants in the BRCA1 and BRCA2 genes. The most common mutation defined in these genes was BRCA1 c.5266dupC; it was detected in 19 women with breast cancer (27 %). The carrier of the pathogenic BRCA1 allele c.4035delA was confirmed in 8 cases (11 %). BRCA1 gene mutations were found to be significantly more common in presence of two or more signs of genetic predisposition to breast cancer. However, among 50 patients with a family medical history of breast and/or ovarian cancer and clinical signs of hereditary cancer, mutations in the BRCA1 and BRCA2 genes were found only in 24 (48 %) cases. Conclusion: The study showed high incidence of germinal BRCA1 mutations (45 %) among breast cancer patients in the western region of Belarus. Only two BRCA1 mutations (c.5266dupC, c.4035delA) are detectable in approximately 84 % of carriers. It is necessary to continue studying the mutations in the genes associated with development of breast cancer that are typical for Belarusian population, especially in the group of young female patients, since this study has confirmed the genetic predisposition only in every third patient under the age of 50.
Downloads
References
Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, Senkus E; ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016 Sep; 27 (suppl 5): v103–v110. https://doi.org/10.1093/annonc/mdw327. Erratum in: Ann Oncol. 2017 Jul 1; 28 (suppl_4): iv167–iv168. PMID: 27664246.
Valencia OM, Samuel SE, Viscusi RK, Riall TS, Neumayer LA, Aziz H. The Role of Genetic Testing in Patients With Breast Cancer: A Review. JAMA Surg. 2017 Jun 1; 152 (6): 589–594. https://doi.org/10.1001/jamasurg.2017.0552. PMID: 28423155.
Cohen-Haguenauer O. Prédisposition héréditaire au cancer du sein (1) - Génétique [Hereditary predisposition to breast cancer (1): genetics]. Med Sci (Paris). 2019 Feb; 35 (2): 138–151. French. https://doi.org/10.1051/medsci/2019003. Epub 2019 Feb 18. PMID: 30774081.
Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international
prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019 Jul 11; 11: 543–561. https://doi.org/10.2147/CLEP.S206949. PMID: 31372057; PMCID: PMC6628947.
Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Mæhle L, Undlien DE, Norum J, Schlichting E. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer. 2017 Jun 21; 17 (1): 438. https://doi.org/10.1186/s12885-017-3422-2. PMID: 28637432; PMCID: PMC5480128.
Moyer VA; U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Feb 18; 160 (4): 271–81. https://doi.org/10.7326/M13-2747. PMID: 24366376.
Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, Warren-Perry M, Eccleston A, Tan MM, Teo SH, Turner N, Strydom A, George A, Rahman N. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. JAMA Netw Open. 2019 May 3; 2 (5): e194428. https://doi.org/10.1001/jamanetworkopen.2019.4428. PMID: 31125106; PMCID: PMC6632150.
Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients / J. Sun [et al.] // Clin. Cancer Res. 2017; 23 (20): 6113–6110. https://doi.org/10.1158/1078-0432.CCR-16-3227.
Paterson R, Phillips KA. Genetic testing in women with breast cancer: implications for treatment. Expert Rev Anticancer Ther. 2017; Nov; 17 (11): 991–1002. https://doi.org/10.1080/14737140.2017.1374175. Epub 2017 Sep 8. PMID: 28853307.
Risks of breast, ovarian and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers /
K. B. Kuchenbaecker [et al.] // JAMA. 2017; 317 (23): 2402–2416.
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies / A. Antoniou [et al.] // Am J Hum Genet. 2003; 72 (5): 1170–1130.
New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. [Electronic resource] / ed.: R. E. Curtis [et al.]. National Cancer Institute, 2006. 492 p. Mode of access: http://seer.cancer.gov/archive/publications/mpmono/. Date of access: 18.12.2020.
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers / M. K. Graeser [et al.] // J Clin Oncol. 2009; 27 (35): 5887–5892.
The contribution of founder mutations in BRCA1 to breast cancer in Belarus / N. Uglanitsa [et al.] // Clin Genet. 2010;78(4):377-380. https://doi.org/10.1111/j.1399-0004.2010.01439.x
High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus / N. V. Bogdanova [et al.] // Clin Genet. 2010; 78 (4): 364–372. https://doi.org/10.1111/j.1399-0004.2010.01473.x
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
